Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug combo fight frailty in HIV?

NCT ID NCT07144293

Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 5 times

Summary

This Phase 2 trial tests whether a combination of dasatinib and quercetin (D+Q) can safely improve physical function in 82 older adults with HIV who are frail or prefrail. Participants take D+Q or a placebo in six 2-day cycles over 12 weeks, then are monitored for another 12 weeks. The study measures side effects, walking speed, and balance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dasatinib and quercetin (D+Q)
What this could lead to
If it works, this could point toward a treatment to reduce frailty and improve physical ability in older people with HIV.
What could go wrong
This is a small, early-phase trial with only 82 participants. The treatment may not work or could cause side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

82 people

The number who actually took part.

Started

Dec 2025

Finished

Aug 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must be an older person with confirmed diagnosis of HIV-1, defined as ≥ 50 years at study entry. 2. Must have been diagnosed with HIV at least 10 years ago, as confirmed by medical records or self-report. 3. Must be on a stable effective combination antiretroviral therapy (ART) regimen, with no changes in the regimen within 12 weeks before joining the study with 2 or more consecutive HIV-RNA levels \< 50 copies/mL within 48 weeks prior to study entry. 4. Must meet one or more Fried Frailty Phenotype criteria w/in 60 days prior to entry. 5. Must have eGFR \> 30 using CKD-EPI per 2021 calculation equation. Exclusion Criteria: 1. Have used quercetin or dasatinib before. 2. Need to take medications that affect CYP3A4 or interact with dasatinib (e.g., certain HIV medications). 3. Have an active cancer (except non-melanoma skin cancer). 4. Have active liver disease with a Child Pugh score greater than 6, or other significant liver problems. 5. Are on dialysis or have had a kidney transplant. 6. Have had a heart attack, angina, stroke, or mini-stroke in the last 6 months. 7. Have a known history of pulmonary arterial hypertension or other respiratory disease requiring supplemental oxygen within 60 days before joining the study. 8. Have uncontrolled diabetes with an HgbA1c level greater than 8% within 60 days before joining the study. 9. Have substance use that might interfere with study participation, as determined by the site investigator. 10. Have had a significant illness within 60 days before joining the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging problems are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Frailty HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging problems Frailty HIV Prefrail

Contacts and locations

Locations

  • Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107)

    Boston, Massachusetts, 02115, United States

  • Case CRS (Site ID: 2501)

    Cleveland, Ohio, 44106, United States

  • Chapel Hill CRS (Site ID: 3201)

    Chapel Hill, North Carolina, 27599, United States

  • Cincinnati CRS (Site ID: 2401)

    Cincinnati, Ohio, 45267-0405, United States

  • Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329)

    New York, New York, 10032, United States

  • Greensboro CRS (Site ID: 3203)

    Greensboro, North Carolina, 27401, United States

  • Harbor University of California Los Angeles Center CRS (Site ID: 603)

    Torrance, California, 90502, United States

  • Houston Advancing Research Team CRS (Site ID: 31473)

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)

    Boston, Massachusetts, 02114, United States

  • New Jersey Medical School Clinical Research Center CRS (Site ID: 31786)

    Newark, New Jersey, 07103, United States

  • Ohio State University CRS (Site ID: 2301)

    Columbus, Ohio, 43210, United States

  • Penn Therapeutics CRS (Site ID: 6201)

    Philadelphia, Pennsylvania, 19104, United States

  • UCSD Antiviral Research Center CRS (Site ID: 701)

    San Diego, California, 92103, United States

  • University of California, Los Angeles CARE Center CRS (Site ID: 601)

    Los Angeles, California, 90035-4709, United States

  • University of California, San Francisco HIV/AIDS CRS (Site ID: 801)

    San Francisco, California, 94143, United States

  • University of Colorado Hospital CRS (Site ID: 6101)

    Aurora, Colorado, 80045, United States

  • University of Pittsburgh CRS (Site ID: 1001)

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787)

    Rochester, New York, 14642, United States

  • University of Washington Positive Research CRS (Site ID: 1401)

    Seattle, Washington, 98104-9929, United States

  • Vanderbilt Therapeutics (VT) CRS (Site ID: 3652)

    Nashville, Tennessee, 37204, United States

  • Washington University Therapeutics (WT) CRS (Site ID: 2101)

    St Louis, Missouri, 63110-1010, United States

  • Weill Cornell Chelsea CRS (Site ID: 7804)

    New York, New York, 10010, United States

  • Weill Cornell Uptown CRS (Site ID: 7803)

    New York, New York, 10065, United States

  • Whitman-Walker Institute, Inc. CRS (Site ID: 31791)

    Washington D.C., District of Columbia, 20009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.